Abbott Laboratories (ABT)

ABT (NYSE:Health Services) EQUITY
neg -0.11
Today's Range: 49.16 - 49.82 | ABT Avg Daily Volume: 4,657,700
Last Update: 07/02/15 - 4:02 PM EDT
Volume: 2,740,289
YTD Performance: 9.75%
Open: $49.80
Previous Close: $49.52
52 Week Range: $39.28 - $50.47
Oustanding Shares: 1,488,757,318
Market Cap: 73,723,262,387
6-Month Chart
TheStreet Ratings Grade for ABT
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 9 9 9
Moderate Buy 3 3 3 4
Hold 5 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.74 1.74 1.74 1.75
Latest Dividend: 0.24
Latest Dividend Yield: 1.94%
Dividend Ex-Date: 07/13/15
Price Earnings Ratio: 37.23
Price Earnings Comparisons:
ABT Sector Avg. S&P 500
37.23 17.90 26.13
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
7.11% 18.23% 52.90%
Revenue -7.30 -0.48 -0.19
Net Income -11.30 -0.64 -0.28
EPS -8.00 -0.50 -0.21
Earnings for ABT:
Revenue 20.25B
Average Earnings Estimates
Qtr (06/15) Qtr (09/15) FY (12/15) FY (12/16)
Average Estimate $0.50 $0.55 $2.16 $2.41
Number of Analysts 12 11 16 16
High Estimate $0.51 $0.57 $2.20 $2.47
Low Estimate $0.50 $0.51 $2.14 $2.35
Prior Year $0.54 $0.62 $2.28 $2.16
Growth Rate (Year over Year) -6.94% -11.00% -5.26% 11.78%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
As health-care stocks rally, it's time for politicians to move on.
The ABBV chart looks constructive, with solid volume and bullish indicators.
You could throw darts at financials and health care and win. 
Apr 24, 2015 | 6:48 AM EDT
ABT - Abbott Laboratories Annual Shareholders Meeting - 10AM
And have we mentioned Greece?

Earnings Growth Boosts AbbVie Real Money Pro($)

Drug franchises are still going strong.
The logic of owning the pure play is attractive.
Jan 30, 2015 | 7:09 AM EST
ABT was upgraded from Neutral to Buy, Bank of America/Merrill Lynch said. $52 price target. Company can deliver strong revenue growth a...
Jan 13, 2015 | 7:18 AM EST
ABT was downgraded from Buy to Hold, Jefferies said. $50 price target. Valuation call, as the company lacks near-term visibility.  ...
It's worth looking at the dividend payers this time of year.

Columnist Conversations

So, why did the markets really get pasted on Monday? I believe it had more to do with the Greek politicians w...
Aetna (AET) is paying .8375 shares plus $125 cash for Humana (HUM). This along with Cigna (CI)-Anthem (ANTM) t...
"Ain't no time to hate, barely time to wait, Wo, oh, what I want to know, where does the time go?" Enjoy July ...
Sorry folks. I received a few queries concerning my earlier note on IMF nullification of the Greek referendum ...


News Breaks

Powered by

Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.